Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan
Drug delivery technologies that improve access and overall efficacy are becoming an essential part of the entire drug development process. Pharmaceutical companies are particularly investing billions of dollars in new vaccine delivery technologies in a bid to move away from needles and syringes to skin delivery procedures.
New analysis from Frost & Sullivan, Needle-Free Nanopatch Vaccines, finds that though the needle-free delivery sector currently makes up a small fraction of the total drug delivery market, the next 5–10 years will see transdermal and intradermal systems (patches and degradable implants), fast-dissolving tablet vaccines, inhalers, and pulmonary delivery methods change the vaccine industry.
While certain forms of needle-free vaccines, such as liquid jet injection, gene guns and micro-needles are already in use, the cell damage caused during administration and the inability to consistently and directly deliver vaccines renders such delivery methods inefficient. Nevertheless, this inefficiency opens doors for vaccine manufacturers to create and commercialise a needle-free system that is not fraught with challenges.
“The delivery of drugs through needle-free devices is gaining acceptance owing to the availability of more formulations for needle-free deliveries,” said Frost & Sullivan Healthcare Research Analyst Swathi Allada. “Significant advancements have been made, most of which have centred on addressing patient comfort levels and increasing the adoption of self-injectable therapies.”
The development of thermostable vaccines with a long shelf life is another area of focus for many vaccine manufacturers, especially for those marketing to nations where cold-chain storage is an issue. The nanopatch, for instance, eliminates the need for refrigeration as the thermostable vaccine is formulated in dry form, making transportation significantly cheaper than traditional needles.
The nanopatch is a micro-needle patch comprising of little, densely packed micro-projections with a defined geometry. Smaller than a postage stamp – and getting smaller – it is capable of directly depositing vaccine to thousands of skin immune cells without causing damage to the cell membrane in the process.
“The nanopatch achieves precise, controlled and consistent skin penetration along with rapid dissolution and diffusion of the vaccine,” noted Allada. “Early-stage tests conducted on mouse models have shown that the nanopatch-delivered flu vaccine is effective even with 1/150th of the dose normally given through a traditional syringe.”
With successful testing in animals, clinical trials on humans will need to be wrapped up to attain FDA approval. Once this happens, the technology will rapidly gain traction both among patients and physicians, ultimately changing the course of vaccine delivery globally.
This Market Insight, Needle-Free Nanopatch Vaccines, is part of the Advanced Medical Technologies Growth Partnership Service program. The Insight covers a range of needle-free vaccine deliveries, discussing drivers for adoption and application scope. The study also details the development and potential of the nanopatch, as well as its impact on the vaccine industry.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance